{"id":"NCT00444925","sponsor":"Pfizer","briefTitle":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)","officialTitle":"12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2007-03-08","resultsPosted":"2009-09-03","lastUpdate":"2015-03-24"},"enrollment":1712,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"fesoterodine fumarate","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tolterodine tartrate","otherNames":[]}],"arms":[{"label":"Fesoterodine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Tolterodine","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder","primaryOutcome":{"measure":"Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-1.46,"sd":0.1},{"arm":"Tolterodine ER","deltaMin":-1.61,"sd":0.06},{"arm":"Fesoterodine","deltaMin":-1.72,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.0107"},{"comp":"OG001 vs OG002","p":"0.0172"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":178,"countries":["United States","Belgium","Brazil","Canada","Chile","Colombia","Costa Rica","Czechia","Denmark","Germany","Greece","Hong Kong","Hungary","India","Italy","Malaysia","Norway","Peru","Poland","Romania","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Ukraine"]},"refs":{"pmids":["37160401","35881009","21428726"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221008&StudyName=Clinical%20Trial%20to%20Evaluate%20the%20Efficacy%20and%20Safety%20of%20Fesoterodine%20in%20Comparison%20to%20Tolterodine%20for%20Overactive%20Bladder"]},"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Dry mouth","Constipation","Headache","Nasopharyngitis","Diarrhoea"]}}